{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/64b7f867cf6b1700110bbf54/68cbdf8bd8e2a59e39a1d816?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Patti's People - Patti Peeples speaks with Melanie Whittington","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/64b7f867cf6b1700110bbf54/1758191441574-006356e3-792f-43d5-bed7-16c0cb3f7e44.jpeg?height=200","description":"<p>In this ‘Patti’s People’ episode, Patti Peeples of the The Peeples Collaborative speaks with Melanie Whittington, Managing Director and Head of the Leerink Center for Pharmacoeconomics, MEDACorp.</p><p><br></p><p>Questions:</p><p><br></p><p>00:00: Introduction</p><p>01:03: You work at the intersection of health economics, policy, and investment. How do these domains influence one another in your work, and what gaps are you aiming to bridge?</p><p>04:34: Who are you informing differently than has been typical?</p><p>07:21: You’ve worked across leading institutions in healthcare. What connects these roles, and what core question or challenge has guided your career??</p><p>09:36: How does traditional cost-effectiveness modeling differ from risk-adjusted NPV models, and do you see a hybrid approach emerging? Who might lead that shift?</p><p>16:11: If you could redesign the value framework, what elements do you think are missing – and why?</p><p>19:27: As a CBO health adviser, what perspective do you bring, and what impact do you hope to make?</p><p>22:12: With policies like the IRA taking shape, are we striking the right balance between cost control and long-term innovation, or are new incentives needed?</p><p>24:55: In your view, what makes healthcare evidence resonate, and why is some data overlooked? </p><p>27:35: As health equity gains attention in economic evaluation, how is HEOR adapting – and where is it still falling short? </p><p>31:02: What advice would you offer to women starting out in health economics today?</p><p>33:45: Rapid fire questions</p><p><br></p><p>Melanie Whittington</p><p>Managing Director and Head of the Leerink Center for Pharmacoeconomics, MEDACorp</p><p><br></p><p>Melanie (Mel) Whittington is a Managing Director and Head of the Leerink Center for Pharmacoeconomics, which is a division of MEDACorp and an affiliate of Leerink Partners. In this role, she leads pharmacoeconomic evaluations of the societal impact of biopharmaceutical innovations. She is also a Senior Fellow within the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center where she is interested in testing novel health economic methods.</p>","author_name":"The Evidence Base"}